Lung Cancer News

MADRID — Amivantamab plus chemotherapy improved PFS, objective response rate and intracranial PFS compared with chemotherapy alone in patients with EGFR-mutated advanced non-small cell lung cancer after progression on osimertinib.

MADRID — Pasi Jänne, MD, PhD, discussed the “encouraging” clinical activity of adagrasib with pembrolizumab in patients with KRAS G12C-mutated advanced non-small cell lung cancer in a video interview with Healio at ESMO Congress.

MADRID — Alectinib significantly improved DFS compared with chemotherapy alone in patients with resected ALK-positive non-small cell lung cancer, according to research presented at ESMO Congress 2023.

MADRID — In this video, Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discussed MARIPOSA data on amivantamab in EGFR-mutated advanced lung cancer presented at ESMO Congress.

MADRID — There were “many exciting updates in EGFR” in the advanced-stage lung cancer setting at ESMO Congress, according to Julia Rotow, MD.

MADRID — In a video interview, Julia Rotow, MD, discussed positive data from the ALINA study in ALK-positive non-small cell lung cancer presented at ESMO Congress.

MADRID — In this video, Julia Rotow, MD, highlighted positive OS data from the KEYNOTE-671 study of a perioperative pembrolizumab regimen for early-stage non-small-cell lung cancer presented at ESMO Congress.

Diagnosing early-stage lung cancer through low-dose CT screening significantly improves its cure rate, according to data published in Radiology.

The FDA announced several regulatory actions.

Researchers identified an association between industry payments to physicians and nonrecommended and low-value drugs in certain clinical scenarios, according to study results published in The BMJ.